RDEA3170 Tablet and Capsule Bioavailability Study

Exclusion Criteria

• - Subject has a history or suspicion of kidney stones.
• - Subject has undergone major surgery within 3 months prior to Screening.
• - Subject donated blood or experienced significant blood loss within 12 weeks prior to Day 1 or gave a plasma donation within 4 weeks prior to Day 1.
• - Subject has clinically unacceptable physical examination, per the Investigator’s judgment.
• - Subject has clinically relevant abnormalities in blood pressure, heart rate, or body temperature, per the Investigator’s judgment.
• - Subject has Screening clinical safety laboratory parameters (serum chemistry [other than serum creatinine and serum urate], hematology, coagulation or urinalysis) that are outside the normal limits and are considered clinically significant by the Investigator.
• - Subject has a serum creatinine value above the upper limit of normal at the Screening visit.
• - Subject has clinically relevant abnormalities in 12-lead electrocardiogram, per the Investigator’s judgment.
• - Subject has a history of cardiac abnormalities
• - Subject cannot swallow multiple tablets or capsules.
• - Subject has received any strong or moderate enzyme-inducing drug or product within 2 months prior to Day 1.